As Biotech Breaks Out, Taking Profits on Some Winners
Research - A tremendous breakout for pharma and biotech stocks is underway, and it makes sense. We’ve discussed this in our recent webinars that we think the … Continue Reading
PremiumAuthor Archives: Jake King
Selecta’s Latest Should Have Horizon’s Attention
Research - Selecta’s (SELB) data, presented at EULAR today, look great. Last week we outlined what to look for. Here’s a quick summary of today’s data. SEL-212 … Continue Reading
Premium
Evaluating A Potentially Better Gout Drug
Research - Editor’s Note – We’ll be transitioning to using Team@PropThink.com for future email communications. Make sure this is added to your address book to insure proper … Continue Reading
Premium
On Revance’s Latest Duration of Benefit Data With RT002
Research - Revance Therapeutics (RVNC) reported topline data from their long-running cervical dystonia study with RT002 last night. Most importantly, all three cohorts (<200units, 200-300 units, and … Continue Reading
Premium
Migraine Space Consolidation Hasn’t Slowed
Research - Sure enough, Sage’s (SAGE) phase 3 STATUS data have leaked into the third quarter. Our suggestion for some August hedge protection may still work, as … Continue Reading
Premium
Sage’s Big Fat Binary Event is Coming Up
Research - Originally sent to PropThink members on May 3, 2017. Selecta Biosciences (SELB) has been weak since our suggestion two weeks ago, but we still like … Continue Reading
Premium
Learning From Savient’s Mess
Research - Many investors will be familiar with the failed commercial efforts at, and subsequent bankruptcy of, Savient Pharmaceuticals (SVNT). It was a spectacle almost a decade … Continue Reading
Premium